Publications by authors named "Rachel Wilcox"
Purpose: Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%.
View Article and Find Full Text PDFArticle Synopsis
- Tisagenlecleucel, a CAR T-cell therapy targeting CD19, has shown remarkable response rates in patients up to age 26 with refractory B-cell acute lymphoblastic leukemia and is FDA approved for this use.
- * A study analyzed data from 185 patients to determine the effects of different CAR T-cell doses on overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS).
- * Results indicated that higher doses of tisagenlecleucel improved survival and remission rates without increasing toxicity, suggesting the potential benefits of targeting higher doses within the approved range for better outcomes.
Article Synopsis
- Infants with B-cell acute lymphoblastic leukemia (B-ALL) face poor treatment outcomes due to chemotherapy resistance, leading to high relapse rates.
- The CAR T-cell therapy, tisagenlecleucel, shows promising results in a study of 14 infants, with 64% achieving remission and 50% remaining in remission long-term.
- The therapy appears to be safe for this age group, with low incidence of severe side effects, suggesting a potential new effective treatment option for aggressive B-ALL in infants.
Purpose: Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy, US Food and Drug Administration-approved for children, adolescents, and young adults (CAYA) with relapsed and/or refractory (RR) B-cell acute lymphoblastic leukemia (B-ALL). The US Food and Drug Administration registration for tisagenlecleucel was based on a complete response (CR) rate of 81%, 12-month overall survival (OS) of 76%, and event-free survival (EFS) of 50%. We report clinical outcomes and analyze covariates of outcomes after commercial tisagenlecleucel.
View Article and Find Full Text PDFChimeric antigen receptor (CAR) T cells have transformed the therapeutic options for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia. Data for CAR therapy in extramedullary (EM) involvement are limited. Retrospective data were abstracted from the Pediatric Real World CAR Consortium (PRWCC) of 184 infused patients from 15 US institutions.
View Article and Find Full Text PDFChimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting in lower nonrelapse mortality and increased survival.
View Article and Find Full Text PDFIntroduction: The aim of this study was to increase student empathy towards hemodialysis patients through an educational intervention that simulates a hemodialysis patient experience.
Methods: Second-year pharmacy students (n = 83) in a required therapeutic module were asked to follow key lifestyle modifications of a hemodialysis patient for two weeks. Students' self-perceived empathy level was assessed using the Kiersma-Chen Empathy Scale (KCES) pre- and post-intervention and post-reflection questions captured students' perceptions of the experience.
Glioblastomas are a subtype of gliomas, which are the most aggressive and deadly form of brain tumours. The epidermal growth factor receptor (EGFR) is over-expressed and amplified in glioblastomas. Luteolin is a common bioflavonoid found in a variety of fruits and vegetables.
View Article and Find Full Text PDF